Comparison of Tyme Technologies Inc. (TYME) and Soligenix Inc. (NASDAQ:SNGX)

Both Tyme Technologies Inc. (NASDAQ:TYME) and Soligenix Inc. (NASDAQ:SNGX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tyme Technologies Inc. N/A 0.00 27.10M -0.27 0.00
Soligenix Inc. 5.27M 2.56 8.16M -0.79 0.00

Demonstrates Tyme Technologies Inc. and Soligenix Inc. earnings per share (EPS), top-line revenue and valuation.


Table 2 represents Tyme Technologies Inc. (NASDAQ:TYME) and Soligenix Inc. (NASDAQ:SNGX)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Tyme Technologies Inc. 0.00% -127.5% -109.1%
Soligenix Inc. -154.84% -160.1% -95.2%

Volatility & Risk

Tyme Technologies Inc.’s 0.05 beta indicates that its volatility is 95.00% less volatile than that of S&P 500. Soligenix Inc.’s 21.00% more volatile than S&P 500 which is a result of the 1.21 beta.


Tyme Technologies Inc. has a Current Ratio of 5.1 and a Quick Ratio of 5.1. Competitively, Soligenix Inc.’s Current Ratio is 2.5 and has 2.5 Quick Ratio. Tyme Technologies Inc.’s better ability to pay short and long-term obligations than Soligenix Inc.

Insider and Institutional Ownership

Roughly 16.3% of Tyme Technologies Inc. shares are held by institutional investors while 22.5% of Soligenix Inc. are owned by institutional investors. Insiders held roughly 0.1% of Tyme Technologies Inc.’s shares. Competitively, Soligenix Inc. has 0.3% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Tyme Technologies Inc. -3.23% -8.54% -52.83% -25.74% -49.15% -59.35%
Soligenix Inc. 12.74% 0.05% -8.37% -24.45% -49.98% -3.37%

For the past year Soligenix Inc. has weaker performance than Tyme Technologies Inc.


On 5 of the 9 factors Soligenix Inc. beats Tyme Technologies Inc.

Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric CrohnÂ’s disease and acute radiation enteritis. This segment also offers SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase IB clinical trial for the treatment of vaccine against ricin toxin poisoning; VeloThrax, an anthrax vaccine candidate; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of melioidosis. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.